← Browse by Condition
Medical Condition
dermatitis atopic
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 3, Phase 2
ClinicalMetric aggregates all active clinical trials for dermatitis atopic from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries. Trials are updated daily as new studies open, status changes, and enrollment targets are updated.
- Recruiting trials — currently enrolling participants, with eligibility criteria
- Phase 1–4 studies — from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary for every trial listing
NCT05391061
Recruiting
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
Enrollment
1,100 pts
Location
South Korea
Sponsor
Pfizer
NCT06488742
Recruiting
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
Enrollment
60 pts
Location
United States
Sponsor
Nexgen Dermatologics, Inc.
NCT06526182 Phase 3
Recruiting
A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Enrollment
520 pts
Location
Spain
Sponsor
Almirall, S.A.
NCT06241118 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Enrollment
390 pts
Location
United States, Argen...
Sponsor
Sanofi
NCT07230860 Phase 2
Recruiting
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
Enrollment
180 pts
Location
United States, Canad...
Sponsor
Janssen Research & Development...
NCT06899204
Recruiting
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Enrollment
150 pts
Location
United States
Sponsor
Pfizer